title: Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
abstract: The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Greenberg
authors.forename: Richard M
authors.initials: RM
authors.lastname: Stone
authors.forename: Aref
authors.initials: A
authors.lastname: Al-Kali
authors.forename: Stefan K
authors.initials: SK
authors.lastname: Barta
authors.forename: Rafael
authors.initials: R
authors.lastname: Bejar
authors.forename: John M
authors.initials: JM
authors.lastname: Bennett
authors.forename: Hetty
authors.initials: H
authors.lastname: Carraway
authors.forename: Carlos M
authors.initials: CM
authors.lastname: De Castro
authors.forename: H Joachim
authors.initials: HJ
authors.lastname: Deeg
authors.forename: Amy E
authors.initials: AE
authors.lastname: DeZern
authors.forename: Amir T
authors.initials: AT
authors.lastname: Fathi
authors.forename: Olga
authors.initials: O
authors.lastname: Frankfurt
authors.forename: Karin
authors.initials: K
authors.lastname: Gaensler
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Griffiths
authors.forename: David
authors.initials: D
authors.lastname: Head
authors.forename: Ruth
authors.initials: R
authors.lastname: Horsfall
authors.forename: Robert A
authors.initials: RA
authors.lastname: Johnson
authors.forename: Mark
authors.initials: M
authors.lastname: Juckett
authors.forename: Virginia M
authors.initials: VM
authors.lastname: Klimek
authors.forename: Rami
authors.initials: R
authors.lastname: Komrokji
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Kujawski
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Maness
authors.forename: Margaret R
authors.initials: MR
authors.lastname: O'Donnell
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Pollyea
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Shami
authors.forename: Brady L
authors.initials: BL
authors.lastname: Stein
authors.forename: Alison R
authors.initials: AR
authors.lastname: Walker
authors.forename: Peter
authors.initials: P
authors.lastname: Westervelt
authors.forename: Amer
authors.initials: A
authors.lastname: Zeidan
authors.forename: Dorothy A
authors.initials: DA
authors.lastname: Shead
authors.forename: Courtney
authors.initials: C
authors.lastname: Smith
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006397:Hematinics / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D060828:Induction Chemotherapy / Q000379:methods; D008495:Medical Oncology / Q000592:standards; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D007155:Immunologic Factors